Braasch Biotech's human anti-obesity vaccine is recognized as important early pipeline vaccine candidate.
Online PR News – 16-August-2010 – – Garretson, South Dakota - Braasch Biotech LLC was recently featured in Business Insights July 2010 Report: Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline.
“Braasch is compiling a diverse portfolio of intellectual property with value tied to the unique scope of our patented Somatostatin vaccines technologies. Our inclusion in the Early Pipeline Vaccine Candidates section of this report is extremely encouraging” stated Keith N. Haffer, Ph.D., president of Braasch. ”Our profile in this internationally respected business market report recognizes the scientific and commercial importance of our human anti-obesity vaccine.”
Braasch Biotech is executing a proactive strategy to continue to build and strengthen a diverse and competitive intellectual property portfolio that provides the company and its partners with a strong proprietary position in the therapeutic vaccine space. The company was recently issued its first US patent and has filed additional patents in the US and Europe for applications of its technologies for obesity, diabetes type 2, myocardial diseases, Rett Syndrome, as well as productivity enhancement vaccines for animal livestock.
About Braasch Biotech LLC. Braasch Biotech, LLC is a privately held preclinical-stage vaccine company that utilizes chimeric somatostatin proteins in optimized adjuvant systems for immunologically increasing endogenous Growth Hormone and Insulin-like Growth Factor-1 (IGF-1). The company is based in the US with headquarters located in South Dakota with additional affiliations in California and Iowa.